💙 🔷 Not impressed by Big Tech in Q3? Explore these Blue Chip Bargains insteadUnlock them all

BioInvent International AB (BINV)

Stockholm
Currency in SEK
Disclaimer
39.250
-3.200(-7.54%)
Closed
BINV Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Fair Value
Day's Range
39.20042.850
52 wk Range
14.00045.400
Bid/Ask
39.25 / 39.25
Prev. Close
42.45
Open
42.45
Day's Range
39.2-42.85
52 wk Range
14-45.4
Volume
86,232
Average Volume (3m)
114,316
1-Year Change
122.51%
Fair Value
Unlock
Fair Value Upside
Unlock
BINV Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
90.000
Upside
+129.299%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week

BioInvent International AB Company Profile

BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. Its drug candidates are BI-1808 is in phase 2 clinical trial and BI-1910 in phase 1 clinical trial for solid tumors targeting Tumor necrosis factor receptor-2 (TNFR2); BI-1206/rituximab in phase 2 clinical trial for the treatment of non-Hodgkin’s lymphoma; BI-1206/pembrolizumab and BI-1607/trastuzumab in phase 1 clinical trial to treat solid tumors targeting FCYRIIB; and BT-001 in phase 1 clinical trial for the treatment of solid tumors targeting Cytotoxic T lymphocyte-associated protein-4. The company has a partnership and collaboration with Transgene to develop BT-001 oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck to evaluate BI-1206, BI-1808, and BT-001 in combination with Keytruda; and licensing agreement with CASI pharmaceuticals for BI-1206. The company was incorporated in 1996 and is based in Lund, Sweden.

Employees
111
Market
Sweden

Compare BINV to Peers and Sector

Metrics to compare
BINV
Peers
Sector
Relationship
P/E Ratio
−6.7x−1.8x−0.6x
PEG Ratio
0.27−0.040.00
Price/Book
2.4x1.6x2.6x
Price / LTM Sales
49.0x19.5x3.1x
Upside (Analyst Target)
129.3%113.9%58.1%
Fair Value Upside
Unlock25.9%9.2%Unlock

FAQ

What Is the BioInvent International (BINV) Stock Price Today?

The BioInvent International stock price today is 39.25

What Stock Exchange Does BioInvent International Trade On?

BioInvent International is listed and trades on the Stockholm stock exchange.

What Is the Stock Symbol for BioInvent International?

The stock symbol for BioInvent International is "BINV."

What Is the BioInvent International Market Cap?

As of today, BioInvent International market cap is 2.58B.

What is BioInvent International Earnings Per Share?

The BioInvent International EPS is -5.82.

What Is the Next BioInvent International Earnings Date?

BioInvent International will release its next earnings report on Oct 31, 2024.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.